New Zealand Formulary
Menu Close Menu

Fewer cancers.
Better survival.
Equity for all.

Systemic Anti-Cancer Therapy Regimen Library

Home > Neuroendocrine tumour Advanced - lanreotide

Neuroendocrine tumour Advanced - lanreotide

Treatment Overview

Cycle 1 (and all further cycles) - 28 days

Cycle length:
28

Cycle details

Cycle 1 (and all further cycles) - 28 days

Medication Dose Route Days Max Duration
lanreotide 120 mg subcutaneous injection 1

Full details

Cycle 1 (and all further cycles) - 28 days

Day: 1

Medication Dose Route Max duration Details
lanreotide 120 mg subcutaneous injection

Supportive Care Factors

No supportive care factors specified

References

Caplin, M. E., M. Pavel, J. B. Cwikla, et al. 2014. "Lanreotide in metastatic enteropancreatic neuroendocrine tumors." N Engl J Med 371(3):224-233., PMID: 25014687

Vinik, A. I., E. M. Wolin, N. Liyanage, et al. 2016. "Evaluation of Lanreotide Depot/Autogel Efficacy and Safety as a Carcinoid Syndrome Treatment (Elect): A Randomized, Double-Blind, Placebo-Controlled Trial." Endocr Pract 22(9):1068-1080, PMID: 27214300

Wolin E.M. P.M., M. Pawel, J.B. Cwikla, et al. 2017. "Final progression-free survival (PFS) analyses for lanreotide autogel/depot 120 mg in metastatic enteropancreatic neuroendocrine tumors (NETs): The CLARINET extension study." J Clin Oncol 35(15):4089-4089.

Martín-Richard, M., B. Massutí, E. Pineda, et al. 2013. "Antiproliferative effects of lanreotide autogel in patients with progressive, well-differentiated neuroendocrine tumours: a Spanish, multicentre, open-label, single arm phase II study." BMC Cancer 13(1):427., PMID: 24053191

Ruszniewski, P., S. Ish-Shalom, M. Wymenga, et al. 2004. "Rapid and sustained relief from the symptoms of carcinoid syndrome: results from an open 6-month study of the 28-day prolonged-release formulation of lanreotide." Neuroendocrinology 80(4):244-251., PMID: 15627802

Kang, J., C. Yoo, H. S. Hwang, et al. 2019. "Efficacy and safety of lanreotide in Korean patients with metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors: a retrospective analysis." Invest New Drugs 37(4):763-770., PMID: 30536151

Ruszniewski, P., J. W. Valle, C. Lombard-Bohas, et al. 2016. "Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study." Dig Liver Dis 48(5):552-558., PMID: 26917486

Ludlam, W. H. and L. Anthony. 2011. "Safety review: dose optimization of somatostatin analogs in patients with acromegaly and neuroendocrine tumors." Adv Ther 28(10):825-841., PMID: 21964965

Pharmacy Retailing (NZ) Ltd t/a Healthcare Logistics. Somatuline Autogel New Zealand Data Sheet 5th April 2024. https://www.medsafe.govt.nz/profs/Datasheet/s/SomatulineAutoGel.pdf (Accessed 10 September 2024).

* The medicines, doses, combinations, and schedule in this treatment regimen have been carefully reviewed against international best practice guidelines by specialists in medical oncology around New Zealand and this advice has been accepted for publication by Te Aho o Te Kahu (the Cancer Control Agency). Sometimes medicines that are used in routine clinical practice have not been through a formal review process by the NZ Medicines Regulator Medsafe and are therefore considered unapproved or off-label. These medicines are legally able to be prescribed through sections 25 and 29 of the Medicines Act and by obtaining informed consent from patients. All treatment regimens listed on this website have been through robust peer review and are considered an accepted standard of care, whether prescribed through sections 25 or 29 or carrying formal Medsafe Approval.

s29: This symbol indicates that some formulations of the associated medicine are legally only able to be prescribed under section 29 of the Medicines Act. You can see which formulations are section 29 by hovering over the s29 symbol. You can access full medication details from the New Zealand Formulary by clicking on the medication name. Each clinician retains full responsibility for ensuring they have complied with all relevant obligations and requirements of section 29 including obtaining informed patient consent prior to prescribing the applicable medicine.